FDA approves Pfizer eczema drug Eucrisa

FDA approved Eucrisa crisaborole (formerly AN2728) from Pfizer Inc. (NYSE:PFE) to treat mild to moderate atopic dermatitis in patients aged two and older. Pfizer spokesperson Steven Danehy said the company plans to launch Eucrisa by the end of January at a wholesale acquisition cost (WAC) of $580 per 60 g tube...